Valdoxan® (Agomelatine): new Evidence Shows Significant Efficacy in Treatment of Anxiety in Depressed Patients (y 2)

            References
        [1] De Bodinat C, et al. Agomelatine, the first melatonergic
        antidepressant: discovery, characterization and development. Nature
        Reviews. Drug Discovery 2010; 9:628-642
        [i] Leproult R, Van Ondergergen A, L'Hermite-Balériaux M et
        al.Phase-shifts of 24-h hormonal release and body temperature following
        early evening administration of the melatonin agonist agomelatine in
        healthy older men. Clin. Endocrinol. 2005;63:298-304
        [ii] Hale A, Corral R, Mencacci O, Saiz Ruiz J, Severo A, Gentil V.
        Superior efficacy of agomelatine vs fluoxetine in severe MDD patients: a
        randomised, double-blind study. J. Eur. College of Neuropsychopharmacol.
        2009;19(suppl 3):S418
        [iii] Leproult R, Van Ondergergen A, L'Hermite-Balériaux M, Van Cautert
        E, Copinschi G. Clin. Endocrinol. 2005;63:298-304
        [iv] Hale A, Corral R, Mencacci O, Saiz Ruiz J, Severo A, Gentil V.
        Superior efficacy of agomelatine vs fluoxetine in severe MDD patients: a
        randomised, double-blind study. J. Eur. College of Neuropsychopharmacol.
        2009;19(suppl 3):S418
        [v] De Bodinat C, et al. Agomelatine , the first melatonergic
        antidepressant : discovery, characterization and development. Nature
        Reviews. Drug Discovery 2010; 9:628-642
        [vi] Goodwin G et al, Agomelatine Prevents Relapse in Patients with Major
        Depressive Disorder Without Evidence of a Discontinuation Syndrome: A
        24-Week Randomized, Double-Blind, Placebo-Controlled Trial. J. Clin.
        Psychiatry. 2009;70(8):1128-1137
        [vii] Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine
        in the Treatment of Major Depressive Disorder: An 8-Week, Multicenter,
        Randomized, Placebo-Controlled Trial J. Clin. Psychiatry.
        2010;71(5):616-626
        [viii] Kasper S et al. Efficacy of the Novel Antidepressant Agomelatine
        on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms
        in Patients with Major Depressive Disorder: A Randomized, Double-Blind
        Comparison with Sertraline. J. Clin. Psychiatry. 2010;71(2):109-120
        [ix] Kennedy S, Rizvi S. Agomelatine in the treatment of major depressive
        disorder: potential for clinical effectiveness. CNS Drugs 2010 Review
        Article
        [x] Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A Double-Blind Comparison
        of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between
        Agomelatine and Venlafaxine XR. J Clin Psychopharmacol. 2008;28:329-333
        [xi] Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I.
        Absence of discontinuation symptoms with agomelatine and occurrence of
        discontinuation symptoms with paroxetine: a randomized, double-blind,
        placebo-controlled discontinuation study. Int Clin Psychopharmacol.
        2004;19:271-280
        [xii] Valdoxan(R) Summary of Product Characteristics

CONTACT: For further information, please contact: Ben Stewart, Tonic LifeCommunications (Tel +44-20-7798-9900) ben.stewart@toniclc.com, orLauraCraggs, Tonic Life Communications (Tel +44-20-7798-9900)laura.craggs@toniclc.com